anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
CIMZIA Lyophilized powder should be prepared and administered by a health care professional. CIMZIA is provided in a package that contains everything required to reconstitute and inject the drug [see How Supplied/Storage and Handling (16)] . Step-by-step preparation and administration instructions are provided below. 

Preparation and Storage

  1. If refrigerated, remove CIMZIA from the refrigerator and allow the vial(s) to sit at room temperature for 30 minutes before reconstituting. Do not warm the vial in any other way. Use appropriate aseptic technique when preparing and administering CIMZIA.
  2. Reconstitute the vial(s) of CIMZIA with 1 mL of Sterile Water for Injection, USP using the 20-gauge needle provided. The sterile water for injection should be directed at the vial wall rather than directly on CIMZIA.
  3. Gently swirl each vial of CIMZIA for about one minute without shaking, assuring that all of the powder comes in contact with the Sterile Water for Injection. The swirling should be as gentle as possible in order to avoid creating a foaming effect.
  4. Continue swirling every 5 minutes as long as non-dissolved particles are observed. Full reconstitution may take as long as 30 minutes. The final reconstituted solution contains 200 mg/mL and should be clear to opalescent, colorless to pale yellow liquid essentially free from particulates.
  5. Once reconstituted, CIMZIA can be stored in the vials for up to 24 hours between 2° to 8° C (36° to 46° F) prior to injection. Do not freeze.



Administration

  1. Prior to injecting, reconstituted CIMZIA should be at room temperature but do not leave reconstituted CIMZIA at room temperature for more than two hours prior to administration.
  2. Withdraw the reconstituted solution into a separate syringe for each vial using a new 20-gauge needle for each vial so that each syringe contains 1 mL of CIMZIA (200 mg of certolizumab pegol).
  3. Replace the 20-gauge needle(s) on the syringes with a 23-gauge(s) for administration.
  4. Inject the full contents of the syringe(s) subcutaneously, by pinching the skin of the thigh or abdomen. Where a 400 mg dose is required, two injections are required, therefore, separate sites should be used for each 200 mg injection.
Acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, has been reported post marketing in patients treated with SOLIQUA 100/33. Some of these events were reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.

Monitor renal function when initiating or escalating doses of SOLIQUA 100/33 in patients with renal impairment and in patients reporting severe gastrointestinal reactions. Advise patients of the potential risk of dehydration due to gastrointestinal adverse reactions and take precautions to avoid fluid depletion. SOLIQUA 100/33 is not recommended in patients with end-stage renal disease [see Use in Specific Populations (8.6)].
A biological indicator analyzer includes a plurality of wells, a plurality of organism detector features, and a user input feature such as a touch screen. Each well is configured to receive a respective biological indicator. Each organism detector feature is configured to detect whether a biological indicator disposed in a corresponding well of the plurality of wells contains a living organism. The touch screen is configured to receive user input and provide information to the user indicating a status of biological indicator analysis. The biological indicator analyzer may be used to analyze a biological indicator that was positioned in a sterilization chamber of a sterilizing cabinet along with at least one medical device that is to be sterilized. The analysis may indicate whether the sterilization cycle in the sterilization chamber as successful.
BACKGROUND: Chronic fatigue syndrome (CFS) has been linked to several conditions, including infections, immune system changes, or emotional stress. Our study aimed to assess the risk of CFS after a pneumonia diagnosis using data from National Health Insurance Research Database of Taiwan.
METHODS: In this nested case-control study, we identified 2,000,000 adult patients from a nationwide population-based health insurance claims database spanning from January 1, 2000, to December 31, 2017. Each case diagnosed with a pathogenic infection was matched with a corresponding control using propensity scores. We excluded individuals under 20 years of age, those with a history of pathogenic infections before the index date, or those with more than one potential pathogen. To estimate hazard ratios (HR) and the adjusted hazard ratio (aHR) with their respective 95 % confidence intervals (CI), we applied univariable and multivariable Cox proportional hazard models. The multivariable analysis incorporated adjustments for age, sex, and comorbidity-related confounders.
RESULTS: The relationship between infection and the subsequent risk of CFS was assessed using Cox proportional hazards regression analysis. The incidence density rates were 6.13 and 8.70 per 1000 person-years among the non-pulmonary infection and pulmonary infection populations, respectively (adjusted hazard ratio [HR] = 1.4, 95 % confidence interval [CI] 1.32-1.5). Patients infected with Pseudomonas, Klebsiella pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, and influenza virus exhibited a significantly higher risk of CFS than those without these pathogens (p < 0.05). Additionally, patients with pneumonia had a significantly increased risk of thromboembolism compare with control group (p < 0.05).
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a medicinal agent used for regulation of metabolic processes associated with deficiency of potassium and magnesium in body and representing the source of bioavailable potassium and magnesium cations. The proposed agent comprises di-(L-aspartate) magnesium, 7÷50 mg/ml; L-aspartate potassium, 11÷50 mg/ml; sorbitol or xylitol, 20÷50 mg/ml and apyrogenic water, pH 6.2÷7.4. Method for preparing the agent is carried out by dissolving L-aspartic acid, magnesium oxide, potassium hydroxide and sorbitol in water for injection at heating. The prepared solution with pH 6.2÷6.8 is subjected for sterilizing filtration, dosing and sterilizing in autoclave. Invention provides the higher bioavailability of potassium and magnesium cations and their assimilability with reducing loading on excretory system of body. EFFECT: improved preparing method, valuable medicinal properties of agent. 5 cl, 4 tbl, 1 dwg, 6 ex
Systems and methods for identifying viral sequences in a subject of a species are provided. Sequence reads not associated with a reference genome of the species are obtained from a biological sample from the subject. At least a portion of each respective sequence read is encoded into a corresponding vector representing all or a portion of the sequence of the respective sequence read, thereby obtaining a plurality of vectors. Each sequence read is assigned a corresponding scalar model score by inputting a vector, in the plurality of vectors, corresponding to the sequence read into a model. Those sequence reads having a corresponding scalar model score that satisfies a first threshold score are selected as contig seeds. The plurality of sequence reads are aligned to these contig seeds through common k-mer sequences thereby forming a plurality of contigs which, in turn, are used to identify viral sequences in the subject.
1,201,052. Vaccine. ELI LILLY & CO. 7 Sept., 1967, No. 40950/67. Heading A5B. A shipping fever vaccine composition comprises a mixture of inactivated cultures of Myxovirus parainfluenza-3, Pasteurella multocida and pasteurella hemolytica a parenterally acceptable antiseptic in a bacteriostatic and fungistatic amount and an amount of an aluminium ion adjuvant comprising aluminium hydroxide gel, aluminium oxide dispersion or aluminium phosphate which is chemically equivalent to an aluminium ion concentration of from 10-50 ml. of an aqueous 1.3% by weight Al 2 O 3  per 100 ml. of the cultures, the mixture having a density of from 5-10 times the optical density of McFarland tube number one on the McFarland test method sale.
ACZONE Gel, 5% and vehicle were evaluated in a randomized, double-blind, cross-over design clinical trial of 64 subjects with G6PD deficiency and acne vulgaris. Subjects were Black (88%), Asian (6%), Hispanic (2%) or of other racial origin (5%). Blood samples were taken at Baseline, Week 2, and Week 12 during both vehicle and ACZONE Gel, 5% treatment periods. There were 56 out of 64 subjects who had a Week 2 blood draw and applied at least 50% of treatment applications. Table 3 contains results from testing of relevant hematology parameters for these two treatment periods. ACZONE Gel was associated with a 0.32 g/dL drop in hemoglobin after two weeks of treatment, but hemoglobin levels generally returned to baseline levels at Week 12.

There were no changes from baseline in haptoglobin or lactate dehydrogenase during ACZONE or vehicle treatment at either the 2-week or 12-week time point.

The proportion of subjects who experienced decreases in hemoglobin ≥1 g/dL was similar between ACZONE Gel, 5% and vehicle treatment (8 of 58 subjects had such decreases during ACZONE treatment compared to 7 of 56 subjects during vehicle treatment among subjects with at least one on-treatment hemoglobin assessment). Subgroups based on gender, race, or G6PD enzyme activity did not display any differences in laboratory results from the overall study group. There was no evidence of clinically significant hemolytic anemia in this study. Some of these subjects developed laboratory changes suggestive of hemolysis.
The cine camera is operated by remote control using an electromagnetic brake to stop the drive at the end of the exposure sequence. The electro-magnet (5) is operated long enough to stop the drive and is open circuit for most of the time to save battery drain. The system is an improvement on existing cameras in which the electro-magnet is under power during the entire exposure sequence. The stopping magnet is linked to an impulse generator (4) which supplies the signal for the braking period. The camera release can be from a remote setting using a simple wire connection. It also allows the camera to be triggered by photocells etc. for special photography.
To survive and establish a niche for themselves, bacteria constantly evolve. Toward that, they not only insert point mutations and promote illegitimate recombinations within their genomes but also insert pieces of 'foreign' deoxyribonucleic acid, which are commonly referred to as 'genomic islands' (GEIs). The GEIs come in several forms, structures and types, often providing a fitness advantage to the harboring bacterium. In pathogenic bacteria, some GEIs may enhance virulence, thus altering disease burden, morbidity and mortality. Hence, delineating (i) the GEIs framework, (ii) their encoded functions, (iii) the triggers that help them move, (iv) the mechanisms they exploit to move among bacteria and (v) identification of their natural reservoirs will aid in superior tackling of several bacterial diseases, including sepsis. Given the vast array of comparative genomics data, in this short review, we provide an overview of the GEIs, their types and the compositions therein, especially highlighting GEIs harbored by two important pathogens, viz. Acinetobacter baumannii and Klebsiella pneumoniae, which prominently trigger sepsis in low- and middle-income countries. Our efforts help shed some light on the challenges these pathogens pose when equipped with GEIs. We hope that this review will provoke intense research into understanding GEIs, the cues that drive their mobility across bacteria and the ways and means to prevent their transfer, especially across pathogenic bacteria.
The system comprises a plurality of users. The plurality of users comprises at least a first user and a second user. The first user has a first user equipment and the second user has a second user equipment. Each user equipment comprises an application for obtaining health status information from its user. Each user equipment is in communication with a server system. The server system is configured to store the health status information of each user and real-time location information of each user. The server system is configured to cause a notification to be sent to at least one of the first user equipment and the second user equipment when a condition is met. The condition is based on the health status information and the real-time location information of the first and second users.
Partial hepatic resection is a feasible and relatively safe procedure for selected patients with benign or malignant hepatobiliary disease. Liver failure after partial hepatic resection, so-called post-resectional liver failure (PLF), is a dreaded complication with high mortality rates. Patients suffering from PLF experience significantly more clinically significant infections (CSI) when compared with patients without PLF. The liver plays an important role in the body's innate immune defense. Recently, polymorphisms in genes encoding key molecules in the innate immune response (e.g. nuclear factor kappa-B) have shown to be associated with a greater risk of CSI. The presence of these polymorphisms combined with partial hepatic resection might render patients susceptible to the development of CSI, PLF and early mortality after liver resection.
LY3039478 given orally TIW in combination with LY3023414 given orally every 12 hours on a 28-day cycle. A single dose of LY3023414 will also be given on day 1 during a 3-day lead-in period.
Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, in particular, to experimental cardiopharmacology, and can be used for modelling and correction of endothelial dysfunction. For this purpose in experiment endothelial dysfunction is modelled by creation of hypoestrogenic condition by bilateral ovariectomy in laboratory animal and during 6 weeks by addition into food of fructose, specific weight of which constitutes 60% of total ration, as well as by daily single irritation by electric current with 10 ms, voltage 30 V, intensity 0.66 mA, passed through electrodes, applied on animal's tail moistened with physiological solution. Degree of endothelial dysfunction development is evaluated by ratio of endothelium-independent and endothelium-dependent vasodilation, and formation of metabolic disorders by change of glycemia level by 120 minute in oral test on tolerance to glucose. Claimed model can be applied for estimation of pharmacological correction of endothelial dysfunction in reproduction of metabolic disorders. ^ EFFECT: method makes it possible to estimate dynamics of formation of endothelial dysfunction in modelling of metabolic disorders with application of fructose-containing diet and electric current. ^ 1 ex, 3 tbl, 1 dwg
BACKGROUND INFORMATION: The precise etiology of breast cancer is not completely understood, although women with BRCA1 gene mutations have a significantly increased risk of developing the disease. In addition, sporadic breast cancer is frequently associated with decreased BRCA1 gene expression. Growing evidence of Human papillomaviruses (HPVs) infections in breast tumors has raised the possibility of the involvement of HPVs in the pathogenesis of breast cancer. We investigated whether the effects of HPV oncoproteins E6 and E7 were influenced by the expression levels of BRCA1. HPV16E6E7 (prototype or E6D25E/E7N29S Asian variant type) were stably expressed in MDA-MB231 breast cancer cells, wild type for BRCA1, or with BRCA1 knocked down.
RESULTS: Expression of HPV16E6E7 oncogenes did not affect BRCA1 levels and the abundance of HPV16E6E7 was not altered by BRCA1 knockdown. BRCA1 levels did not alter HPV16E6E7-dependent degradation of G1-S cell cycle proteins p53 and pRb. However, we found that the expression of G2-M cell cycle protein cyclin B1 enhanced by HPV16E6E7 was impacted by BRCA1 levels. Especially, we found the correlation between BRCA1 and cyclin B1 expression and this was also confirmed in breast cancer samples from a Thai cohort. We further demonstrated that the combination of HPV oncoproteins and low levels of BRCA1 protein appears to enhance proliferation and invasion. Transactivation activities of HPV16E6E7 on genes regulating cell proliferation and invasion (TGF-β and vimentin) were significantly increased in BRCA1-deficient cells.
CONCLUSIONS: Our results indicate that a deficiency of BRCA1 promotes the transactivation activity of HPV16E6E7 leading to increase of cell proliferation and invasion.
SIGNIFICANCE: HPV infection appears to have the potential to enhance the aggressiveness of breast cancers, especially those deficient in BRCA1.
Pathological pain emerges from nociceptive system dysfunction, resulting in heightened pain circuit activity. Various forms of circuitry plasticity, such as central sensitization, synaptic plasticity, homeostatic plasticity, and excitation/inhibition balance, contribute to the malfunction of neural circuits during pain pathogenesis. Recently, a new form of plasticity in the spinal dorsal horn (SDH), named neural circuit polarization (NCP), was discovered in pain models induced by HIV-1 gp120 and chronic morphine administration. NCP manifests as an increase in excitatory postsynaptic currents (EPSCs) in excitatory neurons and a decrease in EPSCs in inhibitory neurons, presumably facilitating hyperactivation of pain circuits. The expression of NCP is associated with astrogliosis. Ablation of reactive astrocytes or suppression of astrogliosis blocks NCP and, concomitantly, the development of gp120- or morphine-induced pain. In this review, we aim to compare and integrate NCP with other forms of plasticity in pain circuits to improve the understanding of the pathogenic contribution of NCP and its cooperation with other forms of circuitry plasticity during the development of pathological pain.
PURPOSE: A chromosomal aberration inhibitor of stem cells, which is treated with an antioxidant is provided to produce a large amount of stem cells and to prevent mutation of cells into tumor cells. CONSTITUTION: A chromosomal aberration inhibitor of stem cells contains an antioxidant as an active ingredient. The antioxidant is vitamin C or catalase. The cell is stem cells derived from embryo, adult, and fetus. The inhibitor suppresses tumorogenesis of the stem cells. A pharmaceutical composition contains the stem cells. The composition is administered by topical injection, oral administration, or parenteral administration.
FIELD: medicine. ^ SUBSTANCE: invention provides use of polypeptide antigens and/or automembrane vesicles (OMV) Neisseria meningitidis for immunisation against meningococci of serogroup A, C, W135 and Y (and particularly against meningococci of serogroup Y). According to the invention, polypeptides of meningococci of serogroup B are able to provide protection from meningococci of all serogroups A, B, C, W135 and Y, preferentially Y. These polypeptides and/or automembrane vesicles provide a basis to created immunogenic compositions for immunisation from infection caused by Neisseria meningitidis of serogroup Y and the other. Said immunogenic compositions under the invention provide protection against infection Neisseria meningitides of serogroups A, B, C, W135 and/or Y. ^ EFFECT: application of the invention allows for protection against the diseases caused by Neisseria meningitides with using as active component polypeptides Neisseria of serogroup B only, instead of a number of capsulat polysaccharide antigens which do not provide protection from Neisseria of serogroup B. ^ 5 cl
This study is a prospective, post-market evaluation of the performance of the DiLumen C2 Endolumenal Interventional Platform ("C2 device") used as an endoscopic dual balloon accessory device used to ensure complete positioning, visualization, and diagnosis in endoscopic treatments in the large intestine. The DiLumen Endolumenal Interventional Knife ("IK device") and the DiLumen Endolumenal Interventional Grasper ("IG device") are disposable instruments used with the C2 device. These devices are cleared by the US Food and Drug Administration (FDA) for commercial use in endolumenal therapies and will be used on-label in this study. The overall goal of this study is to evaluate the clinical performance of the C2 device and its related instruments. Intra-procedure parameters (procedure timepoints, anesthesia use, polyp location and description), final pathology/histology, and general complications will also be evaluated. Investigators will also be asked to assess the ease of use of the C2Interventional Platform.

To accomplish this goal, up to 100 subjects will be enrolled at up to 5 clinical sites and treated using the C2 device and related instruments. Evaluations will be performed pre-procedure, during the procedure, and at discharge. Assessments will include polyp classification/pathology, procedure timepoints, final pathology/histology, adverse events, and ease of use. As per the FDA cleared product labeling this study will be limited to subjects undergoing an endoscopic procedure to remove polyps in the large intestine.
Ultrasound guided sacroiliac joint injection of 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml). Single injection per course is being given.
The pathogenesis of diabetes is accompanied by increased levels of inflammatory factors, also known as "metabolic inflammation", which runs through the whole process of the occurrence and development of the disease. Mitochondria, as the key site of glucose and lipid metabolism, is often accompanied by mitochondrial function damage in type 2 diabetes mellitus (T2DM). Damaged mitochondria release pro-inflammatory factors through damage-related molecular patterns that activate inflammation pathways and reactions to oxidative stress, further aggravate metabolic disorders, and form a vicious circle. Currently, the pathogenesis of diabetes is still unclear, and clinical treatment focuses primarily on symptomatic intervention of the internal environment of disorders of glucose and lipid metabolism with limited clinical efficacy. The proinflammatory effect of mitochondrial damage-associated molecular pattern (mtDAMP) in T2DM provides a new research direction for exploring the pathogenesis and intervention targets of T2DM. Therefore, this review covers the most recent findings on the molecular mechanism and related signalling cascades of inflammation caused by mtDAMP in T2DM and discusses its pathogenic role of it in the pathological process of T2DM to search potential intervention targets.